Sourcing · Regulatory · continued

Prescription requirements and telehealth models posts 91–98

Sourcing › Regulatory FDA compounding research use only MHRA

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.

c.rasmussenTL226 Dec 2025#91

On prescription requirements and telehealth models I would separate what is worth knowing from what is worth acting on. The first list is long and the second is short, and conflating them is how threads get heated.

3 likes 7mo

j.nascimentoTL226 Dec 2025#92

Reporting rather than recommending, on prescription requirements and telehealth models. What happened is above. Whether it should have is a different question and not one I am qualified to answer.

10 likes 7mo

c.bakkerTL226 Dec 2025#93

n.achebe, post #59: Building on post #56 rather than restating it. A methods point on prescription requirements and telehealth models rather than a substantive one: if the comparison is not like for like, the difference you are measuring is the difference in method. Go to post

Taking post #90 at face value and following it one step further.

Where a claim about legality is made here, the useful follow-up is which instrument it rests on. Most such claims turn out to rest on a forum post.

I have left out the parts I could not verify.

31 likes in reply to #59 7mo

c.ramosTL227 Dec 2025#94

The honest answer on prescription requirements and telehealth models is that it depends, and the useful part is the list of what it depends on. Four items, in rough order of how much they matter.

Most people get the first two right and then argue about the fourth.

0 likes 7mo

t.demirTL227 Dec 2025#95

What I can speak to on prescription requirements and telehealth models is narrow, so I will keep it narrow rather than generalising from it. Beyond that boundary I do not know.

6 likes 7mo

e.silvaTL228 Dec 2025 · edited#96

f.sjoberg, post #29: Everything in post #26 holds. The case it does not cover is the one I have. The reason prescription requirements and telehealth models is hard to answer is that the obvious measurement and the relevant quantity are not the same thing, and substituting one for the other is silent. Go to post

Generic or biosimilar entry depends on patent and exclusivity positions that are jurisdiction-specific and are frequently misreported.

16 likes in reply to #29 7mo

an.adeyemiTL228 Dec 2025#97

t.verhoeven, post #51: Where a claim about legality is made here, the useful follow-up is which instrument it rests on. Most such claims turn out to rest on a forum post. Go to post

Useful. I had the fact and not the reason, which turns out to be the important half.

0 likes in reply to #51 7mo

e.lokkenTL229 Dec 2025#98

Worth separating two things that post #96 runs together.

Counterpoint on prescription requirements and telehealth models, offered without confidence: the same observation is consistent with a much duller explanation, and nobody has ruled the dull one out.

1 like 7mo

This topic was referenced in

What a regulator's shortage notice actually authorisesSourcing › Regulatory · 12 replies
Second pass at: Import rules for personal quantities, by jurisdiction, datedSourcing › Regulatory · 2 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
Follow-up: How compounding permissions changed when supply normalised Sourcing › Regulatory MHRA personal import research use only How compounding permissions changed when supply normalised I have a specific reason for asking rather than idle curiosity, and the context is below. I was wrong about compounding permissions in a thread last…	+72	77	1.5k	1d
Reading a regulatory notice rather than an article about it — what changed since Sourcing › Regulatory research use only MHRA FDA personal import Reading a regulatory notice rather than an article about it — what changed since — setting out what I have, and where I think it stops being reliable. Asking what a regulator's document actually says, since…	+28	32	640	13mo
Pharmaceutical compounding rules, summarised from primary sources — a second dataset Sourcing › Regulatory MHRA research use only compounding Posting this under the heading it deserves: Pharmaceutical compounding rules, summarised from primary sources — a second dataset Everything below is what sits behind that. Asking what a regulator's document…	+50	56	780	8mo
Enforcement priorities versus written rules Sourcing › Regulatory FDA personal import MHRA Enforcement priorities versus written rules — setting out what I have, and where I think it stops being reliable. Asking what a regulator's document actually says, since the summaries of it disagree. I have…		2	62k	15mo
Second pass at: Import rules for personal quantities, by jurisdiction, dated Sourcing › Regulatory research use only personal import FDA MHRA Second pass at: Import rules for personal quantities, by jurisdiction, dated Writing it up because I had to work it out twice and would rather nobody else did. Asking what a regulator's document actually…		2	5k	11mo

Related topics — sharing the tags FDA, compounding, research use only

Topic	Participants	Replies	Views	Activity
Import rules for personal quantities, by jurisdiction, dated Sourcing › Regulatory compounding MHRA FDA personal import On the subject in the title: Import rules for personal quantities, by jurisdiction, dated Working notes rather than a conclusion. I was wrong about import rules for personal quantities in a thread last spring…		3	60k	12mo
Coming back to: When "no data" is the complete and final answer Compounds › Other compounds research use only needs a source custom synthesis When "no data" is the complete and final answer I have a specific reason for asking rather than idle curiosity, and the context is below. Asking about the compound itself rather than about a trial of it. I…	+77	82	12k	11mo
Manufacturer assistance programmes and their eligibility rules Access › Pricing formulary data table compounding On the subject in the title: Manufacturer assistance programmes and their eligibility rules Working notes rather than a conclusion. I have spent a fortnight trying to pin manufacturer assistance programmes…	+37	42	32k	11d
Managing an unplanned gap in supply Access › Shortages shortage formulary FDA compounding Managing an unplanned gap in supply — setting out what I have, and where I think it stops being reliable. A narrow question about managing an unplanned gap, deliberately narrow, because the broad version has…	+105	110	5.1k	3mo
Cost per milligram, computed honestly across formats — the long version Access › Pricing cost per milligram compounding formulary data table Cost per milligram, computed honestly across formats — the long version Writing it up because I had to work it out twice and would rather nobody else did. Documenting an access outcome, dated, because…	+111	124	24k	14mo